New drug ALMB-0166 tested for spinal cord injury safety
Disease control
Completed
This early-stage study tested a single dose of the drug ALMB-0166 in 24 adults who had a recent spinal cord injury. The main goal was to see if the drug is safe and how the body processes it. Participants received either the drug or a placebo after spinal surgery.
Phase: PHASE1 • Sponsor: AlaMab Therapeutics (Shanghai) Inc. • Aim: Disease control
Last updated May 15, 2026 11:57 UTC